Advanced Medical Isotope (RDGL)
(Delayed Data from OTC)
$0.19 USD
+0.01 (4.79%)
Updated Jun 14, 2024 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Advanced Medical Isotope Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 3 | 3 | 3 | 1 | 1 |
Income After Depreciation & Amortization | -3 | -3 | -3 | -1 | -1 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -3 | -2 | -3 | -1 | -2 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -3 | -2 | -3 | -1 | -2 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -3 | -2 | -3 | -1 | -2 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -3 | -3 | -3 | -1 | -1 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -3 | -3 | -3 | -1 | -1 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 368.81 | NA | 325.85 | 222.80 | NA |
Diluted EPS Before Non-Recurring Items | -0.01 | NA | -0.01 | 0.00 | NA |
Diluted Net EPS (GAAP) | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 |
Fiscal Year end for Advanced Medical Isotope Corporation falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
Cost Of Goods | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 |
Gross Profit | 0.00 | -0.01 | 0.01 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.58 | 0.93 | 0.69 | 0.91 | 0.25 |
Income After SG&A, R&D, and Dept/Amort Expenses | -0.58 | -0.94 | -0.68 | -0.91 | -0.25 |
Non-Operating Income | 0.02 | 0.02 | 0.02 | 0.01 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -0.56 | -1.08 | -0.67 | -0.90 | -0.25 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -0.56 | -1.08 | -0.67 | -0.90 | -0.25 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -0.56 | -1.08 | -0.67 | -0.90 | -0.25 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 389.41 | 368.81 | 370.54 | 368.17 | NA |
Diluted EPS Before Non-Recurring Items | 0.00 | -0.01 | 0.00 | 0.00 | NA |
Diluted Net EPS (GAAP) | 0.00 | -0.01 | 0.00 | 0.00 | NA |